BioMarin Pharmaceutical Newswire

Comprehensive Real-Time News Feed for BioMarin Pharmaceutical.

Results 1 - 20 of 149 in BioMarin Pharmaceutical

  1. Here's how the government pushes companies to treat kids and rare diseasesRead the original story

    9 hrs ago | Seattle Post-Intelligencer

    BioMarin Pharmaceutical in Novato and San Rafael has six more months to keep exclusively selling a new, kid-friendly form of its drug for a disease called phenylketonuria.

    Comment?

  2. BioMarin Pharmaceutical Inc. To Host First Quarter 2014 Financial...Read the original story

    17 hrs ago | BioSpace

    BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, at 5:00 p.m. ET to discuss first quarter 2014 financial results and provide a general business update.

    Comment?

  3. Herea s how the government pushes companies to treat kids and rare diseasesRead the original story

    15 hrs ago | SFGate

    BioMarin Pharmaceutical in Novato and San Rafael has six more months to keep exclusively selling a new, kid-friendly form of its drug for a disease called phenylketonuria.

    Comment?

  4. Zacks Reiterates "Neutral" Rating for BioMarin PharmaceuticalRead the original story

    Yesterday | AmericanBankingNews.com

    ... other analysts have also recently weighed in on BMRN. Analysts at Goldman Sachs downgraded shares of BioMarin Pharmaceutical from a "buy" rating to a "neutral" rating in a research note on Monday, March 24th. They now have a $84.00 price target on ...

    Comment?

  5. Analysts View on Biotech Equities -- Research on Organovo Holdings,...Read the original story

    Tuesday | Sys-Con Media

    ... has initiated coverage on the following equities: Organovo Holdings Inc. (NYSE MKT: ONVO), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI). Free technical ...

    Comment?

  6. FDA Extends Market Exclusivity Six Months For BioMarin Pharmaceutical ...Read the original story

    Monday Apr 14 | BioSpace

    BioMarin Pharmaceutical Inc. , a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that the Food and Drug Administration granted KUVANA Powder for Oral Solution and Tablets a six-month pediatric exclusivity extension.

    Comment?

  7. FDA Extends Market Exclusivity of KUVAN Powder for Oral Solution and TabletsRead the original story

    Monday Apr 14 | Pharmaceutical Processing

    BioMarin Pharmaceutical today announced that the FDA granted KUVAN Powder for Oral Solution and Tablets a six-month pediatric exclusivity extension.

    Comment?

  8. Report Published: "Spinal Cord Injury - Pipeline Review, H1 2014"Read the original story

    Friday Apr 11 | SBWire

    ... Mentioned in this Report: Athersys, Inc., Quark Pharmaceuticals, Inc., Acorda Therapeutics, Inc., BioMarin Pharmaceutical Inc., TCA Cellular Therapy, LLC, Lpath, Inc., Bukwang Pharmaceutical Co., Ltd., Asubio Pharmaceuticals, Inc., D-Pharm Ltd., ...

    Comment?

  9. Clinical Trial Results and Initiation, Endowment, Product Launches,...Read the original story

    Friday Apr 11 | Sys-Con Media

    Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. , Questcor Pharmaceuticals, Inc. , Jazz Pharmaceuticals plc , Ariad Pharmaceuticals, Inc. , and BioMarin Pharmaceutical Inc. .

    Comment?

  10. Cramer's Lightning Round - The IPOs Are A Curse On The MarketRead the original story

    Friday Apr 11 | Seeking Alpha

    Service Corporation : "We have been faithful to Service Corporation in the funeral home industry.

    Comment?

  11. San Rafael conceptually approves six-story parking garage for BioMarinRead the original story

    Thursday Apr 10 | Marin Independent Journal

    San Rafael's Design Review Board has conceptually approved a plan by BioMarin Pharmaceutical to build a six-story parking garage across from the San Rafael Corporate Center bordered by Second Street and Lincoln Avenue.

    Comment?

  12. The AACR Annual Meeting May Move These 2 StocksRead the original story

    Monday Apr 7 | The Motley Fool

    ... LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all ...

    Comment?

  13. Clinovo Release: Silicon Valley BioTalks - Manage Outsourced And In House Clinical TrialsRead the original story

    Tuesday Apr 1 | BioSpace

    March 31, 2014 -- Outsourcing experts from Onyx Pharmaceuticals, San Francisco State University , BioMarin Pharmaceutical, and Clinovo discussed the topic 'Manage In-house and Outsourced Clinical Trials: Vendor Selection, Project Coordination, and Resource Management' at the eighth Silicon Valley BioTalks.

    Comment?

  14. Ultragenyx plans to double Marin staffRead the original story

    Monday Mar 31 | The Business Journal

    ... in facilities," Mr. Kassberg said. Another Novato-based developer of rare-disorder treatments, BioMarin Pharmaceutical, has spent hundreds of dollars per square foot to establish and expand its Novato production facilities. Because the BioMarin and ...

    Comment?

  15. Avoid Applied Genetic Technologies IPORead the original story

    Wednesday Mar 26 | Seeking Alpha

    ... that the former includes the likes of Sanofi SA ( SNY ), uniQure BV ( QURE ), Audentes Therapeutics, BioMarin Pharmaceutical Inc ( BMRN ), Celladon Corp ( CLDN ), and Spark Therapeutics, among others; the latter includes Genzyme, Gensight, Neurotech ...

    Comment?

  16. BioMarin Pharmaceutical Price Target Increased to $76.00 by Analysts at WedbushRead the original story

    Tuesday Mar 25 | AmericanBankingNews.com

    ... Wedbush's target price points to a potential upside of 5.48% from the stock's previous close. BioMarin Pharmaceutical ( NYSE:BMRN ) traded down 2.25% on Tuesday, hitting $72.05. The stock had a trading volume of 3,210,156 shares. BioMarin ...

    Comment?

  17. Stock Downgrades: JPMorgan Drives the Corner Store Round the BendRead the original story

    Tuesday Mar 25 | Minyanville

    ... Neutral from Overweight at HSBC Securities. Its price objective, previously $39, gets trimmed by $4. BioMarin Pharmaceutical ( NASDAQ:BMRN ): Amid a brutal time for biotechs, Goldman Sachs pulls the firm from its America's Buy list. Coal Companies : ...

    Comment?

  18. Goldman Sachs Downgrades BioMarin Pharmaceutical to NeutralRead the original story

    Monday Mar 24 | AmericanBankingNews.com

    Shares of BioMarin Pharmaceutical traded down 0.30% during mid-day trading on Monday, hitting $73.71.

    Comment?

  19. New Market Research Report: BioMarin Pharmaceutical, Inc. - Mergers & ...Read the original story

    Friday Mar 21 | SBWire

    ... undertaken by an organization to sustain its competitive advantage. Report Description: MarketLines' BioMarin Pharmaceutical, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed ...

    Comment?

  20. BioMarin Pharmaceutical Inc. Appoints Pioneer In Personalized Medicine, To Board Of DirectorsRead the original story

    Friday Mar 21 | BioSpace

    BioMarin Pharmaceutical Inc. , a global leader in providing therapies for rare genetic diseases, today announced the appointment of Dennis J. Slamon, M.D., Ph.D., director of Clinical/Translational Research and director of the Revlon/UCLA Women's Cancer Research Program at UCLA's Jonsson Comprehensive Cancer Center, to the company's board of ... (more)

    Comment?